Daniel B. Brown, MD, FSIR

Where Does IO Stand in the NCCN Guidelines: ICC

Daniel B. Brown , MD, FSIR;

02/16/2022

Where Does IO Stand in the NCCN Guidelines: Panel Discussion

Nima Kokabi , MD;

Ahmed K. Abdel Aal , MD, PhD;

Nicholas Fidelman , MD;

Alda L. Tam , MD, FRCPC, MBA;

Nadine Abi-Jaoudeh , MD;

Daniel B. Brown , MD, FSIR;

02/16/2022

Liver Metastatic Disease: 2022 Year in Review

Daniel Brown, MD, FSIR reviews noteworthy 2022 studies on liver metastatic disease at the Symposium on Clinical Interventional Oncology.

Daniel B. Brown , MD, FSIR;

01/04/2023

Interventional Oncology 2016: The State of the Union Is Good!

01/22/2017

Daniel B. Brown , MD, FSIR;

Interventional Radiology (IR) has had an historic year, receiving the first new primary specialty designation awarded by the American Board of Medical Specialties in over 25 years. In parallel, the University of Miami took the extraordinary...

Interventional Radiology (IR)...

01/22/2017

IO Learning

Clinical Insights

US RESiN Registry for the Study and Evaluation of Patients Treated With SIR-Spheres

06/29/2016

Filip Banovac , MD;

Daniel B. Brown , MD, FSIR;

Abstract: Background: Yttrium-90 (Y90) is increasingly used to treat both primary and secondary liver tumors that are ineligible for resection. In the United States, Y90 resin microspheres (SIR-Spheres; Sirtex Medical) are FDA approved for...

Abstract: Background: Yttrium-90...

06/29/2016

IO Learning

Interview

Interventional Oncology 2016: The State of the Union Is Good!

11/04/2016

Daniel B. Brown , MD, FSIR;

Interventional Radiology (IR) has had a historic year, receiving the first new primary specialty designation awarded by the American Board of Medical Specialties in over 25 years. In parallel, the University of Miami took the extraordinary...

Interventional Radiology (IR)...

11/04/2016

IO Learning

My Approach to a Patient with Metastatic Colorectal Cancer

Daniel Brown, MD, FSIR, Vice-Chair, Innovation and Clinical Research, Vanderbilt University Medical Center discusses his approach to a patient with metastatic colorectal cancer.

Daniel B. Brown , MD, FSIR;

07/29/2021